Alight, Inc.

Alight, Inc. (NYSE: ALIT) is a leading cloud-based integrated digital human capital and business solutions provider. Fees paid by clients for services are the primary source of revenue. It provides solutions using a combination of proprietary, partner technology and a well-developed provider network.

Key Highlights

• The company reported a 3.29% increase in total revenues to USD 690 million in Q3FY21 (ended September 30, 2021) compared to USD 668 million in Q3FY20.
• ALIT reported an increase in net losses to USD 120 million in Q3FY21 from USD 39 million in Q3FY20.
• As of September 30, 2021, the company had cash and cash equivalents of USD 769 million with total outstanding debt of USD 2.88 billion, indicating a highly leveraged balance sheet.
• ALIT announced on December 16, 2021, that it would reinvent the healthcare benefits experience by combining clinical healthcare navigation with its engagement platform.
• The stock is now trading between its key short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 49.50.
• Stock is leaning towards the lower band of the 52-week range of USD 8.46 to USD 14.51.
• The stock remained relatively stable throughout the year. However, in the past three months, ALIT corrected ~9.03%.

Technical Price Chart (as of December 22, 2021). Analysis by Kalkine

Conclusion: Considering the increase in losses, margins pressure, and technical indicators, we recommend an "Watch" rating on the stock at the closing price of USD 10.48, up 0.29% as of December 22, 2021.

*The reference data in this report has been partly sourced from REFINITIV.

Biomerica, Inc.

Biomerica, Inc. (NASDAQ: BMRA) operates as a  biomedical technology company, which develops, patents, manufactures, and sells diagnostic and therapeutic solutions for the early identification and monitoring of chronic diseases and other illnesses.

Key Highlights

• The company reported YoY growth of 10.31% in net sales to USD 1.26 million in Q1FY22 (ended August 31, 2021) compared to USD 1.14 million in Q1FY21.
• BMRA's net loss reduced to USD 1.54 million during Q1FY22 vs. USD 1.89 million in Q1FY21.
• As of August 31, 2021, the company had cash and cash equivalents of USD 5.00 million and no outstanding debt.
• Negative Net Margin of 122.3% in Q1FY22 vs. industry median of 6.1%.
• As per its preliminary release on December 16, 2021, BMRA estimates revenue of ~USD 4.6 million in the Q2FY22, a 238% YoY growth over revenue of ~USD 1.4 million in the Q2FY21.
• On November 19, 2021, BMRA announced that Dr. Brooks Cash, one of the well-known leaders in gastroenterology medicine, has volunteered to chair BMRA's newly formed Colorectal Cancer Scientific Advisory Board (SAB).
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• The stock is leaning towards the lower end of its 52-week range of USD 3.30 to USD 8.15.
• BMRA's stock price decreased 8.68% and 4.12% in the past one and three months, respectively.

Technical Price Chart (as of December 22, 2021). Analysis by Kalkine

Conclusion: Considering the topline growth, long-term profitability issues, technical indicators, and associated risks, we recommend a "Watch" rating on the stock at the current price of USD 4.42, up 1.14%, as of December 22, 2021, 03:55 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.